Talkspace, Inc.
NASDAQ:TALKMedical - Care Facilities
+$0.01 today
- Market cap
- $879.44M
- Beta
- 1.07
- P/E (TTM)
- 749.9
- EPS (TTM)
- $0.01
Volume 2.41M
Average 2.55M
TALK Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Talkspace, Inc.NASDAQ: TALK
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow declines year over year
Q1 FY2026 financing cash flow of $730K (cash outflow) fell 88.5% year over year, behind the -28.5% change in trailing-twelve-month financing cash flow. Sequentially, it rose 45.4% from the prior quarter.
Context
- Financing cash flow amounted to 8.3% of revenue in FY2025, up 1.8 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -88.5% toward the trailing-twelve-month pace of -28.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (19M) USD
- Year-over-year change
- -55.9%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (19M) | -55.9% |
| FY2024 | 2024-12-31 | (12.19M) | -742.5% |
| FY2023 | 2023-12-31 | 1.9M | +12.7% |
| FY2022 | 2022-12-31 | 1.68M | -99.3% |
| FY2021 | 2021-12-31 | 251.38M | — |
Financing Cash Flow vs competitors
How TALK compares with its peers on the latest reported figures
- TALK's LTM Mar 2026 financing cash flow of $13.37M is the 6th largest of the 11 companies compared; the peer median is $5.57M.
- Its year-over-year change of -28.5% is the 8th highest of 10, against a peer median of +228.2%.
- Financing cash flow amounts to 5.6% of revenue for TALK, versus a peer median of 5.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.27B | +228.2% | +38.6% | 5.9% | |
| LTM Mar 2026 | $1.07B | +433.7% | — | 259.6% | |
| LTM Mar 2026 | $362.11M | +157.4% | +413.4% | — | |
| LTM Mar 2026 | $49.7M | +542.7% | +396.9% | 122.4% | |
| LTM Dec 2025 | $22.93M | — | — | 19.8% | |
| LTM Mar 2026 | $13.37M | -28.5% | — | 5.6% | |
| LTM Mar 2026 | $11.1M | -85.7% | — | 1.6% | |
| LTM Mar 2026 | $10.8M | +25.0% | -54.9% | 3.6% | |
| LTM Mar 2026 | $8.51M | -38.3% | +44.5% | 0.9% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $6.95M | +2116.1% | — | 71.2% |
| LTM Mar 2026 | $4.19M | +5344.2% | -74.0% | 2.8% | |
| Peer median (excluding TALK) | $5.57M | +228.2% | +41.6% | 5.9% | |
Competitors are the stored peer set for TALK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (62.74M) | (79.67M) | (19.18M) | 1.15M | (5.22M) |
| Depreciation & Amortization | 1.97M | 1.36M | 1.2M | 859K | 2.88M |
| Deferred Income Tax | (31.78M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 27.41M | 12.12M | 8.4M | 9.17M | 8.45M |
| Change in Working Capital | (738K) | 2.12M | (7.55M) | 895K | (8.23M) |
| Accounts Receivables | 402K | (4.13M) | (534K) | 531K | (6.42M) |
| Inventory | (3.66M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 503K | (968K) | (350K) | 1.6M | 791K |
| Other Working Capital | 2.01M | 7.21M | (6.67M) | (1.24M) | (2.6M) |
| Other Non-Cash Items | 175K | 3M | 748K | (371K) | 10.66M |
| Operating Cash Flow | (65.71M) | (61.08M) | (16.39M) | 11.7M | 8.53M |
| Capital Expenditures | (663K) | (350K) | (151K) | (5.44M) | (10.64M) |
| Acquisitions (Net) | 0 | 33K | 10K | 0 | (4.9M) |
| Purchases of Investments | 0 | 0 | 0 | (41.12M) | (49.34M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 36.08M |
| Other Investing Activities | 0 | 0 | 0 | (171K) | (10.71M) |
| Investing Cash Flow | (663K) | (317K) | (141K) | (46.73M) | (28.88M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 251.43M | 3.18M | 2.71M | 2.01M | 913K |
| Common Stock Repurchased | 0 | 0 | 0 | (11M) | (17.2M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (50K) | (1.5M) | (810K) | (1.19M) | (2.71M) |
| Financing Cash Flow | 251.38M | 1.68M | 1.9M | (12.19M) | (19M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 185.01M | (59.71M) | (14.64M) | (47.22M) | (39.34M) |
| Free Cash Flow | (66.37M) | (61.43M) | (16.54M) | 6.26M | (2.11M) |
Talkspace, Inc.
NASDAQ:TALK
Intrinsic Alpha fair value
Locked
Current Price
$5.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.